NASDAQ:GRPH - Graphite Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.67
  • Forecasted Upside: 41.38 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$24.52
▼ -0.47 (-1.88%)

This chart shows the closing price for GRPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Graphite Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRPH

Analyst Price Target is $34.67
▲ +41.38% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Graphite Bio in the last 3 months. The average price target is $34.67, with a high forecast of $35.00 and a low forecast of $34.00. The average price target represents a 41.38% upside from the last price of $24.52.

This chart shows the closing price for GRPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Graphite Bio.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/20/2021Morgan StanleyInitiated CoverageOverweight$35.00High
7/20/2021SVB LeerinkInitiated CoverageOutperform$34.00High
7/20/2021CowenInitiated CoverageOutperformHigh
7/20/2021Bank of AmericaInitiated CoverageBuy$35.00High
(Data available from 7/23/2016 forward)
Graphite Bio logo
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $24.52
Low: $24.20
High: $26.56

50 Day Range

MA: N/A

52 Week Range

Now: $24.52
Low: $18.45
High: $34.00

Volume

216,829 shs

Average Volume

572,319 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Graphite Bio?

The following Wall Street research analysts have issued stock ratings on Graphite Bio in the last twelve months: Bank of America Co., Cowen Inc, Morgan Stanley, and SVB Leerink LLC.
View the latest analyst ratings for GRPH.

What is the current price target for Graphite Bio?

3 Wall Street analysts have set twelve-month price targets for Graphite Bio in the last year. Their average twelve-month price target is $34.67, suggesting a possible upside of 40.4%. Morgan Stanley has the highest price target set, predicting GRPH will reach $35.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $34.00 for Graphite Bio in the next year.
View the latest price targets for GRPH.

What is the current consensus analyst rating for Graphite Bio?

Graphite Bio currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRPH will outperform the market and that investors should add to their positions of Graphite Bio.
View the latest ratings for GRPH.

What other companies compete with Graphite Bio?

How do I contact Graphite Bio's investor relations team?

The company's listed phone number is 650-484-0886 and its investor relations email address is [email protected] The official website for Graphite Bio is www.graphitebio.com.